Medical Cannabis Prescription Process to Be Streamlined by NHSE
NHS England has announced plans to streamline the medical cannabis prescription process, including the introduction of a centralised digital portal for specialist prescribers and standardised patient eligibility criteria. The changes, expected to roll out later in 2026, aim to reduce administrative delays and improve communication between clinics, pharmacies and patients.
NHS England has announced a package of reforms designed to streamline the medical cannabis prescription process, including the development of a centralised digital portal for specialist prescribers and the introduction of standardised patient eligibility criteria across all prescribing services.
The reforms, confirmed following a consultation with the Association of Medical Cannabis Clinicians and patient advocacy groups, are expected to be phased in during the second half of 2026. They represent the most significant administrative update to the UK prescribing framework since medical cannabis was legalised in November 2018.
Key Changes Announced
The centrepiece of the reform package is a new digital prescribing portal that will allow specialist clinicians to submit, track and manage cannabis prescriptions in a single system, replacing the current patchwork of clinic-specific processes and paper-based workflows. The portal will also provide real-time visibility of product availability across dispensing pharmacies, reducing delays caused by stock shortages.
Standardised eligibility criteria will aim to reduce variability in prescribing decisions across clinics, providing clearer guidance for conditions including chronic pain, treatment-resistant epilepsy, multiple sclerosis and PTSD. Clinics will retain clinical discretion, but the new framework will provide a national baseline.
Patient Impact
NHS England estimates that the reforms could reduce average prescription processing time by up to 30%, with faster communication between prescribers, pharmacies and patients. The changes are also expected to improve data collection, feeding into ongoing research and policy development around medical cannabis outcomes in the UK.
